# EDGAR Filing Document

**Accession Number:** 0002048877
**File Stem:** 0001213900-25-062759
**Filing Date:** 2025-7
**Character Count:** 5585
**Document Hash:** db82725d42765cabacbd10b590ae02a0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-062759.hdr.sgml**: 20251121

**ACCESSION NUMBER**: 0001213900-25-062759

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250710

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** YD Bio Ltd
- **CENTRAL INDEX KEY:** 0002011674
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039
- **BUSINESS PHONE:** 619-500-7747

**MAIL ADDRESS:**
- **STREET 1:** 955 WEST JOHN CARPENTER FREEWAY
- **STREET 2:** SUITE 100-929
- **CITY:** IRVING
- **STATE:** TX
- **ZIP:** 75039

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** True Velocity, Inc./DE
- **DATE OF NAME CHANGE:** 20240209
**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** YD Biopharma Ltd
- **CENTRAL INDEX KEY:** 0002048877
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 12F., NO. 3, XINGNAN ST.
- **STREET 2:** NANGANG DIST.
- **CITY:** TAIPEI CITY
- **STATE:** F5
- **ZIP:** 115001
- **BUSINESS PHONE:** 88623820030

**MAIL ADDRESS:**
- **STREET 1:** 12F., NO. 3, XINGNAN ST.
- **STREET 2:** NANGANG DIST.
- **CITY:** TAIPEI CITY
- **STATE:** F5
- **ZIP:** 115001

---

| | |
|:---|:---|
| ![](image_001.jpg) | **ArentFox Schiff LLP** |
| ![](image_001.jpg) | 1717 K Street, NW |
| ![](image_001.jpg) | Washington, DC 20006 |
| ![](image_001.jpg) | 202.857.6000 **main** |
| ![](image_001.jpg) | 202.857.6395 **fax** |
| ![](image_001.jpg) | afslaw.com |

---

---

| |
|:---|
| **Marc Rivera** |
| Partner |
| 202.350.3643 **direct** |
| marc.rivera@afslaw.com |

---

---

| |
|:---|
| July 10, 2025 |
| **<u>VIA EDGAR</u>** |
| United States Securities and Exchange Commission |
| Division of Corporation Finance |
| Office of Industrial Applications and Services |
| 100 F Street, NE |
| Washington, DC 20549 |

---

Attention: Christie Wong, Michael Fay, Jane Park and Margaret Sawicki

---

| | |
|:---|:---|
| **Re:** | **YD Bio Limited** |

---

**Amendment No. 7 to Registration Statement on Form F-4**

**Filed July 7, 2025**

**File No. 333-283428**

Ladies and Gentlemen:

This letter is being submitted on behalf of YD Bio Limited (the "<u>Company</u>") in response to the comment letter, dated July 9, 2025, of the staff of the Division of Corporation Finance (the "<u>Staff</u>") of the Securities and Exchange Commission (the "<u>Commission</u>") with respect to Amendment No. 7 to Registration Statement on Form F-4 filed on July 7, 2025 (the "<u>Registration Statement</u>"). Concurrently with this response, the Company has filed Amendment No. 8 to the Registration Statement on Form F-4/A pursuant to the Staff's comments (the "<u>Amended Registration Statement</u>").

***<u>Amendment No. 7 to Form F-4 filed July 7, 2025</u>***

***<u>Exhibits</u>***

1.  ***We note Assumption 2(n) in the legal opinion filed as Exhibit 5.1: "the issue of any Offering Shares pursuant to the Registration Statement and the Merger Agreement, and the issue of the Warrant Shares upon the exercise of the Warrants pursuant to the Merger Agreement and the Warrant Agreement at the time of issuance, whether as principal issue or on the conversion, exchange or exercise of any Ordinary Shares or Warrants, would not result in the Company exceeding its then authorised share capital; and upon the issue of any such Ordinary Shares, the Company will receive consideration for the full issue price thereof which shall be equal to at least the par value thereof." Please remove this assumption as counsel can not assume that the registrant has sufficient authorized shares. Refer to Section II.B.3.a of Staff Legal Bulletin No. 19.*** 

---

| | |
|:---|:---|
| RESPONSE: | The Company respectfully acknowledges the Staff's comment and advises the Staff that the above referenced assumption has been removed from the Exhibit 5.1 opinion and replaced in its entirety with an assumption that the authorized share capital of the Company will not change before the issuance of the Offering Shares and Warrant Shares. |

---

2.  ***We note that Pubco Warrants are registered pursuant to this registration statement, and the only legal opinion opining on the registered securities, filed as Exhibit 5.1, does not opine on the Pubco Warrants. Please advise whether a separate legal opinion opining on the Pubco Warrants will be filed. Refer to Staff Legal Bulletin No. 19.*** 

 ****

RESPONSE: The Company respectfully acknowledges the Staff's comment and advises the Staff that a separate legal opinion opining on the Pubco Warrants has been filed as Exhibit 5.2 to the Amended Registration Statement.

\* \* \*

\* \* \*

---

| | |
|:---|:---|
| ![](image_001.jpg) | July 10, 2025<br> Page 2 |

---

Should you have any questions regarding the foregoing, please do not hesitate to contact Marc Rivera at (202) 350-3643.

Sincerely,

ARENTFOX SCHIFF LLP

---

| | |
|:---|:---|
| *<u>/s/ Marc Rivera</u>* | *<u>/s/ Marc Rivera</u>* |
| By: | Marc Rivera |

---

Enclosures